{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:02:57Z","timestamp":1789498977950,"version":"build-2803163510"},"reference-count":71,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,1,2]],"date-time":"2022-01-02T00:00:00Z","timestamp":1641081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Children"],"abstract":"<jats:p>The three types of neurofibromatosis, namely type 1, type 2, and schwannomatosis, are generally associated with various benign tumors affecting the skin and the nervous system. On rare occasions, especially in patients with neurofibromatosis type 1 (NF1), malignant neoplasms may also be present, several of them possessing a more aggressive course than in individuals without this syndrome. As such, a clear delineation between the three variants of neurofibromatosis is crucial to establish the correct diagnosis and management, as well as predict the neoplasm-related outcomes. Neurofibromin, the principal product of the NF1 gene, is a potent inhibitor of cellular proliferation, having been linked to several key signaling pathways involved in tumor growth. Therefore, it may provide a useful therapeutic target for tumor management in these patients. In this article, we want to present the association between deficiency of neurofibromin and the consequences of the lack of this protein leading to different kinds of malignant tumors. The therapy is still uncertain and most therapeutic options are in development or clinical trials.<\/jats:p>","DOI":"10.3390\/children9010040","type":"journal-article","created":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T22:51:50Z","timestamp":1641250310000},"page":"40","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Neurofibromatosis in Children: Actually and Perspectives"],"prefix":"10.3390","volume":"9","author":[{"given":"Maria Lucia","family":"Sur","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Iuliu Hatieganu University of Medicine and Pharmacy, 400006 Cluj-Napoca, Romania"},{"name":"Children Emergency Clinical Hospital, 400006 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5965-539X","authenticated-orcid":false,"given":"Ionel","family":"Armat","sequence":"additional","affiliation":[{"name":"Cardiovascular and Transplant Emergency Institute of T\u00e2rgu Mure\u0219, 540136 Targu Mures, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genel","family":"Sur","sequence":"additional","affiliation":[{"name":"Children Emergency Clinical Hospital, 400006 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana-Cristina","family":"Pop","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Iuliu Hatieganu University of Medicine and Pharmacy, 400006 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7645-0716","authenticated-orcid":false,"given":"Gabriel","family":"Samasca","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Iuliu Hatieganu University of Medicine and Pharmacy, 400006 Cluj-Napoca, Romania"},{"name":"Children Emergency Clinical Hospital, 400006 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iulia","family":"Lupan","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology, Babes-Bolyai University, 400084 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4776-7247","authenticated-orcid":false,"given":"Teodora-Larisa","family":"Timis","sequence":"additional","affiliation":[{"name":"Department of Physiology, Iuliu Hatieganu University of Medicine and Pharmacy, 400006 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7730-338X","authenticated-orcid":false,"given":"Ioan-Alexandru","family":"Florian","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Iuliu Hatieganu University of Medicine and Pharmacy, 400006 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0926-4614","authenticated-orcid":false,"given":"Daniel","family":"Sur","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Iuliu Hatieganu University of Medicine and Pharmacy, 400006 Cluj-Napoca, Romania"},{"name":"Institute of Oncology \u201cIon Chiricuta\u201d, 400015 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,2]]},"reference":[{"key":"ref_1","unstructured":"Le, C., and Bedocs, P.M. (2021). Neurofibromatosis, StatPearls Publishing."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1097\/CORR.0000000000001239","article-title":"Germline Mutations for Novel Candidate Predisposition Genes in Sporadic Schwannomatosis","volume":"478","author":"Min","year":"2020","journal-title":"Clin. Orthop. Relat. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1136\/jnnp-2018-318538","article-title":"Schwannomatosis: A genetic and epidemiological study","volume":"89","author":"Evans","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_4","first-page":"e16512","article-title":"Complications of Neurofibromatosis 1 (NF1) in an Adult with Multiple Comorbid-ities","volume":"13","author":"Nnomadim","year":"2021","journal-title":"Cureus"},{"key":"ref_5","unstructured":"Messersmith, L., and Krauland, K. (2021). Neurofibroma, StatPearls Publishing."},{"key":"ref_6","first-page":"e14258","article-title":"Chronic Lymphocytic Leukemia in Neurofibromatosis Type 1 Patients: Case Report and Literature Review of a Rare Occurrence","volume":"13","author":"Cohen","year":"2021","journal-title":"Cureus"},{"key":"ref_7","first-page":"5575957","article-title":"An Unusual Association between Neurofibromatosis Type 1 and Diffuse B Cell Lymphoma","volume":"2021","author":"Bizanti","year":"2021","journal-title":"Case Rep. Oncol. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ijscr.2019.08.020","article-title":"Mediastinal malignant triton tumor: A rare case series and review of literature","volume":"62","author":"Chaudhry","year":"2019","journal-title":"Int. J. Surg. Case Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/j.radcr.2021.04.019","article-title":"Malignant triton tumor of the anterior mediastinum: A rare tumor in a rare location","volume":"16","author":"Zain","year":"2021","journal-title":"Radiol. Case Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"rjz246","DOI":"10.1093\/jscr\/rjz246","article-title":"Malignant triton tumor of the left thoracic cavity: A case report","volume":"2019","author":"Ishikawa","year":"2019","journal-title":"J. Surg. Case Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"229","DOI":"10.5114\/fn.2018.78704","article-title":"A rare case of intracranial malignant triton tumor arising in the middle cranial fossa: A case report and review of the literature","volume":"56","author":"Bruzzone","year":"2018","journal-title":"Folia Neuropathol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"201","DOI":"10.5414\/NP301314","article-title":"Malignant transformation of NF1-associated spinal astrocytoma with loss of ATRX expression during the course: A case report","volume":"40","author":"Yuzawa","year":"2021","journal-title":"Clin. Neuropathol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e25346","DOI":"10.1097\/MD.0000000000025346","article-title":"Glioblastoma in a female neurofibromatosis 1 patient without IDH1, BRAF V600E, and TERT promoter mutations","volume":"100","author":"Cai","year":"2021","journal-title":"Medicine"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e210945","DOI":"10.1001\/jamanetworkopen.2021.0945","article-title":"Comparison of Cancer Prevalence in Patients with Neurofibromatosis Type 1 at an Academic Cancer Center vs in the General Population From 1985 to 2020","volume":"4","author":"Landry","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/exd.13212","article-title":"Neurofibromatosis type 1 (NF1) gene: Beyond caf\u00e9 au lait spots and dermal neurofibromas","volume":"26","author":"Peltonen","year":"2017","journal-title":"Exp. Dermatol."},{"key":"ref_16","first-page":"297","article-title":"Neurofibromin in neurofibromatosis type 1\u2014Mutations in NF1 gene as a cause of disease","volume":"18","author":"Abramowicz","year":"2014","journal-title":"Dev. Period Med."},{"key":"ref_17","first-page":"2050313X17741016","article-title":"The importance of pheochromocytoma case detection in patients with neurofibromatosis type 1: A case report and review of literature","volume":"5","author":"Tate","year":"2017","journal-title":"SAGE Open Med. Case Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1158\/1541-7786.MCR-19-0147","article-title":"Malignant Peripheral Nerve Sheath Tumors: From Epigenome to Bedside","volume":"17","author":"Korfhage","year":"2019","journal-title":"Mol. Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/B978-0-444-64076-5.00051-X","article-title":"Neurofibromatosis type 1","volume":"148","author":"Cimino","year":"2018","journal-title":"Handb. Clin. Neurol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2147\/BCTT.S111397","article-title":"Increased risk of breast cancer in neurofibromatosis type 1: Current insights","volume":"9","author":"Howell","year":"2017","journal-title":"Breast Cancer Targets Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.tins.2012.12.002","article-title":"Modeling cognitive dysfunction in neurofibromatosis-1","volume":"36","author":"Gutmann","year":"2013","journal-title":"Trends Neurosci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1634\/theoncologist.5-6-477","article-title":"Malignancy in Neurofibromatosis Type 1","volume":"5","author":"Korf","year":"2000","journal-title":"Oncologist"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/pde.13064","article-title":"Association between Juvenile Myelomonocytic Leukemia, Juvenile Xanthogran-ulomas and Neurofibromatosis Type 1: Case Report and Review of the Literature","volume":"34","author":"Paulus","year":"2017","journal-title":"Pediatr. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.2169\/internalmedicine.53.2012","article-title":"Coexistence of Gastro-intestinal Stromal Tumors (GISTs) and Pheochromocytoma in Three Cases of Neurofibromatosis Type 1 (NF1) with a Review of the Literature","volume":"53","author":"Gorgel","year":"2014","journal-title":"Intern. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/B978-0-444-62702-5.00004-4","article-title":"Neurofibromatosis type 1","volume":"132","author":"Anderson","year":"2015","journal-title":"Handb. Clin. Neurol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/ajmg.a.61069","article-title":"Substantial pain burden in frequency, intensity, interference and chronicity among children and adults with neurofibromatosis Type 1","volume":"179","author":"Kongkriangkai","year":"2019","journal-title":"Am. J. Med Genet. Part A"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1055\/s-0036-1579766","article-title":"Neurofibromatosis: A Review of NF1, NF2, and Schwannomatosis","volume":"5","author":"Walsh","year":"2016","journal-title":"J. Pediatr. Genet."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Tamura, R. (2021). Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22115850"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/humu.24261","article-title":"Pathogenic noncoding variants in the neurofibromatosis and schwannomatosis predisposition genes","volume":"42","author":"Evans","year":"2021","journal-title":"Hum. Mutat."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"17004","DOI":"10.1038\/nrdp.2017.4","article-title":"Neurofibromatosis type 1","volume":"3","author":"Gutmann","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1001\/archopht.125.3.389","article-title":"Ocular Pathologic Findings of Neurofibromatosis Type 2","volume":"125","author":"McLaughlin","year":"2007","journal-title":"Arch. Ophthalmol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"W646","DOI":"10.2214\/AJR.12.8577","article-title":"Schwannomatosis: The overlooked neurofibromatosis?","volume":"200","author":"Koontz","year":"2013","journal-title":"Am. J. Roentgenol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1038\/s41436-021-01170-5","article-title":"Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: An international consensus recommendation","volume":"23","author":"Legius","year":"2021","journal-title":"Genet. Med."},{"key":"ref_34","unstructured":"Tiwari, R., and Singh, A.K. (2021). Neurofibromatosis Type 2, StatPearls Publishing."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.mcna.2019.07.004","article-title":"The Diagnosis and Management of Neurofibromatosis Type 1","volume":"103","author":"Ly","year":"2019","journal-title":"Med. Clin. N. Am."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/S1470-2045(09)70033-6","article-title":"Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1","volume":"10","author":"Brems","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1093\/neuros\/nyab019","article-title":"Pathological Features of Tumors of the Nervous System in Hereditary Cancer Predisposition Syndromes: A Review","volume":"89","author":"Tadros","year":"2021","journal-title":"Neurosurgery"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1055\/s-0034-1382021","article-title":"Neurofibromatosis type 1 (NF1) and Associated Tumors","volume":"226","author":"Rosenbaum","year":"2014","journal-title":"Klin. P\u00e4diatrie"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/s12957-020-02036-x","article-title":"Prognosis and risk factors for malignant peripheral nerve sheath tumor: A systematic review and meta-analysis","volume":"18","author":"Cai","year":"2020","journal-title":"World J. Surg. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3171\/2015.12.JNS152443","article-title":"Patterns of recurrence and survival in sporadic, neurofibromatosis Type 1\u2013associated, and radiation-associated malignant peripheral nerve sheath tumors","volume":"126","author":"Watson","year":"2017","journal-title":"J. Neurosurg."},{"key":"ref_41","first-page":"439","article-title":"Clinicopathological features and prognosis of malignant peripheral nerve sheath tumor: A retrospective study of 140 cases","volume":"39","author":"Yuan","year":"2017","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3171\/2015.6.JNS15596","article-title":"Tumors of the peripheral nervous system: Analysis of prognostic factors in a series with long-term follow-up and review of the literature","volume":"125","author":"Montano","year":"2016","journal-title":"J. Neurosurg."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1200\/JCO.2016.71.7199","article-title":"CNS Tumors in Neurofibromatosis","volume":"35","author":"Campian","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/B978-0-444-52902-2.00053-9","article-title":"Neurofibromatosis type 1 (NF1): Diagnosis and management","volume":"115","author":"Ferner","year":"2013","journal-title":"Handb. Clin. Neurol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1158\/1078-0432.CCR-17-0589","article-title":"Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 1","volume":"23","author":"Evans","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/0883073817739509","article-title":"Optic Pathway Gliomas in Neurofibromatosis Type 1","volume":"33","author":"Campen","year":"2017","journal-title":"J. Child Neurol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3171\/2010.11.SPINE10350","article-title":"Spinal ependymomas in neurofibromatosis Type 2: A retrospective analysis of 55 patients","volume":"14","author":"Plotkin","year":"2011","journal-title":"J. Neurosurg. Spine"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/ajmg.a.38675","article-title":"2016 Children\u2019s Tumor Foundation conference on neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis","volume":"176","author":"Fisher","year":"2018","journal-title":"Am. J. Med. Genet. A"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"vdaa153","DOI":"10.1093\/noajnl\/vdaa153","article-title":"New developments in neurofibromatosis type 2 and vestibular schwannoma","volume":"3","author":"Ren","year":"2020","journal-title":"Neuro-Oncol. Adv."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"103148","DOI":"10.1016\/j.amjoto.2021.103148","article-title":"Reliability and toxicity of bevacizumab for neurofibromatosis type 2-related vestibular schwannomas: A systematic review and meta-analysis","volume":"42","author":"Shi","year":"2021","journal-title":"Am. J. Otolaryngol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1001\/jamaneurol.2017.1406","article-title":"Association of Genetic Predisposition with Solitary Schwannoma or Meningioma in Children and Young Adults","volume":"74","author":"Pathmanaban","year":"2017","journal-title":"JAMA Neurol."},{"key":"ref_52","unstructured":"Alruwaili, A.A., and De Jesus, O. (2021). Meningioma, StatPearls Publishing."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1200\/JCO.2015.65.3576","article-title":"Distinctive Cancer Associations in Patients with Neurofibromatosis Type 1","volume":"34","author":"Uusitalo","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s13023-021-01856-8","article-title":"Lymphoproliferative malignancies in patients with neurofibromatosis 1","volume":"16","author":"Bergqvist","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1530\/EJE-16-0233","article-title":"Interest of systematic screening of pheochromocytoma in patients with neuro-fibromatosis type 1","volume":"175","author":"Mognetti","year":"2016","journal-title":"Eur. J. Endocrinol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/bjc.2016.403","article-title":"Breast cancer in neurofibromatosis type 1: Overrepresentation of unfavourable prognostic factors","volume":"116","author":"Uusitalo","year":"2016","journal-title":"Br. J. Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s10549-018-4851-6","article-title":"Breast cancer in women with neurofibromatosis type 1 (NF1): A comprehensive case series with molecular insights into its aggressive phenotype","volume":"171","author":"Yap","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/jid.2014.465","article-title":"Incidence and Mortality of Neurofibromatosis: A Total Population Study in Finland","volume":"135","author":"Uusitalo","year":"2015","journal-title":"J. Investig. Dermatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/labinvest.2016.142","article-title":"The NF1 gene in tumor syndromes and melanoma","volume":"97","author":"Kiuru","year":"2017","journal-title":"Lab. Investig."},{"key":"ref_60","first-page":"34","article-title":"Neurofibromatosis von Recklinghausen type 1 (NF1)\u2014Clinical picture and molecular-genetics diagnostic","volume":"51","author":"Kraus","year":"2015","journal-title":"Cesk. Patol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/MOP.0000000000000169","article-title":"Neurofibromatosis-related tumors: Emerging biology and therapies","volume":"27","author":"Karajannis","year":"2015","journal-title":"Curr. Opin. Pediatr."},{"key":"ref_62","first-page":"101","article-title":"Advanced pharmacological therapies for neurofibromatosis type 1-related tumors","volume":"91","author":"Naso","year":"2020","journal-title":"Acta Bio Med. Atenei Parm."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/14728222.2018.1465931","article-title":"Emerging therapeutic targets for neurofibromatosis type 1","volume":"22","author":"Walker","year":"2018","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1093\/neuonc\/nov200","article-title":"Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis","volume":"18","author":"Blakeley","year":"2016","journal-title":"Neuro-Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Woycinck Kowalski, T., Brussa Reis, L., Finger Andreis, T., Ashton-Prolla, P., and Rosset, C. (2020). Systems Biology Approaches Reveal Potential Phenotype-Modifier Genes in Neurofibromatosis Type 1. Cancers, 12.","DOI":"10.3390\/cancers12092416"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1053\/j.gastro.2016.12.002","article-title":"Genome-Wide CRISPR Screen Identifies Regulators of Mito-gen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice","volume":"152","author":"Song","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1093\/neuonc\/noaa201","article-title":"Opportunities for the treatment of NF1-associated low-grade gliomas: How to decide on the best treatment options for patients?","volume":"22","author":"Mueller","year":"2020","journal-title":"Neuro-Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/13543784.2021.1857363","article-title":"Systemic therapy of advanced\/metastatic gastrointestinal stromal tumors: An update on progress beyond imatinib, sunitinib, and regorafenib","volume":"30","author":"Mohammadi","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.3892\/etm.2021.10531","article-title":"Antiproliferative therapy with sirolimus and propranolol for congenital vascular anomalies in newborns (Case reports)","volume":"22","author":"Bizubac","year":"2021","journal-title":"Exp. Ther. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","article-title":"Selumetinib in Children with Inoperable Plexiform Neurofibromas","volume":"382","author":"Gross","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"12310","DOI":"10.1073\/pnas.1600914113","article-title":"Physical interaction between neurofibromin and serotonin 5-HT6 receptor promotes receptor constitutive activity","volume":"113","author":"Nadim","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Children"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9067\/9\/1\/40\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:35:55Z","timestamp":1760362555000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9067\/9\/1\/40"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,2]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1]]}},"alternative-id":["children9010040"],"URL":"https:\/\/doi.org\/10.3390\/children9010040","relation":{},"ISSN":["2227-9067"],"issn-type":[{"value":"2227-9067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,2]]}}}